Visiomed blows hot

By Graeme O'Neill
Thursday, 13 January, 2005

Shares in Visionmed (ASX:VSG) rose 1.3 cents to 4.4 cents today, before relaxing to 4.3 cents, on news that the Perth medical-device company is gearing up to market and distribute its Funhaler asthma spacer device for children in the US.

Visionmed is expecting pre-market clearance from the US Food and Drug Administration this month, after US clinical trials confirmed it performed at least as well as current market-leading spacers.

A spacer is a device designed to ensure asthma patients use their asthma inhaler correctly, and receive an appropriate dose. The toy-like Funhaler incorporates a whistle and spinning disc, that provide a sensory reward for children who use their inhaler correctly.

The company plans to launch the Funhaler in the US market in the first half of 2005. Australia's Therapeutic Goods Administration has already approved its use in Australia, with distribution expected to begin this month or next. Visionmed will seek approval within the next six weeks to launch the device in Europe.

Related News

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...

Life expectancy gains are slowing, study finds

Life expectancy at birth in the world's longest-living populations has increased by an...

Towards safer epilepsy treatment for pregnant women

New research conducted in organoids is expected to provide pregnant women with epilepsy safer...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd